These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 30826330)
1. Inhibition of MMPs and ADAM/ADAMTS. Malemud CJ Biochem Pharmacol; 2019 Jul; 165():33-40. PubMed ID: 30826330 [TBL] [Abstract][Full Text] [Related]
2. ADAMTS and ADAM metalloproteinases in osteoarthritis - looking beyond the 'usual suspects'. Yang CY; Chanalaris A; Troeberg L Osteoarthritis Cartilage; 2017 Jul; 25(7):1000-1009. PubMed ID: 28216310 [TBL] [Abstract][Full Text] [Related]
3. A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease. Zhong S; Khalil RA Biochem Pharmacol; 2019 Jun; 164():188-204. PubMed ID: 30905657 [TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases (MMPs) in health and disease: an overview. Malemud CJ Front Biosci; 2006 May; 11():1696-701. PubMed ID: 16368548 [TBL] [Abstract][Full Text] [Related]
5. MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm. Li Y; Wang W; Li L; Khalil RA Life Sci; 2020 Jul; 253():117659. PubMed ID: 32283055 [TBL] [Abstract][Full Text] [Related]
6. Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to Improve Current Therapies. Itoh Y Prog Mol Biol Transl Sci; 2017; 148():327-338. PubMed ID: 28662826 [TBL] [Abstract][Full Text] [Related]
7. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Cawston TE; Wilson AJ Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):983-1002. PubMed ID: 16980219 [TBL] [Abstract][Full Text] [Related]
8. Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (MMPs) and disintegrin metalloproteinases (ADAMs) by articular cartilage chondrocytes. Flannery CR; Little CB; Caterson B; Hughes CE Matrix Biol; 1999 Jun; 18(3):225-37. PubMed ID: 10429942 [TBL] [Abstract][Full Text] [Related]
9. Aggravation of ADAMTS and matrix metalloproteinase production and role of ERK1/2 pathway in the interaction of osteoarthritic subchondral bone osteoblasts and articular cartilage chondrocytes -- possible pathogenic role in osteoarthritis. Prasadam I; Crawford R; Xiao Y J Rheumatol; 2012 Mar; 39(3):621-34. PubMed ID: 22247346 [TBL] [Abstract][Full Text] [Related]
10. Matrix-degrading metalloproteinases and their roles in joint destruction. Okada Y Mod Rheumatol; 2000 Sep; 10(3):121-8. PubMed ID: 24383588 [TBL] [Abstract][Full Text] [Related]
11. A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹⁸F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging. Matusiak N; Castelli R; Tuin AW; Overkleeft HS; Wisastra R; Dekker FJ; Prély LM; Bischoff R; van Waarde A; Dierckx RA; Elsinga PH Bioorg Med Chem; 2015 Jan; 23(1):192-202. PubMed ID: 25438884 [TBL] [Abstract][Full Text] [Related]
12. Metalloproteinases: their role in arthritis and potential as therapeutic targets. Clark IM; Parker AE Expert Opin Ther Targets; 2003 Feb; 7(1):19-34. PubMed ID: 12556200 [TBL] [Abstract][Full Text] [Related]
13. ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease. Yang H; Khalil RA Adv Pharmacol; 2022; 94():255-363. PubMed ID: 35659374 [TBL] [Abstract][Full Text] [Related]
14. [Progress of research in osteoarthritis. Metalloproteinases in osteoarthritis]. Okada A; Okada Y Clin Calcium; 2009 Nov; 19(11):1593-601. PubMed ID: 19880991 [TBL] [Abstract][Full Text] [Related]
15. Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis. Milner JM; Rowan AD; Cawston TE; Young DA Arthritis Res Ther; 2006; 8(5):R142. PubMed ID: 16919164 [TBL] [Abstract][Full Text] [Related]
16. CCAAT/enhancer binding protein β regulates expression of matrix metalloproteinase-3 in arthritis. Tsushima H; Okazaki K; Hayashida M; Ushijima T; Iwamoto Y Ann Rheum Dis; 2012 Jan; 71(1):99-107. PubMed ID: 21917825 [TBL] [Abstract][Full Text] [Related]
17. The role of ADAMTSs in arthritis. Lin EA; Liu CJ Protein Cell; 2010 Jan; 1(1):33-47. PubMed ID: 21203996 [TBL] [Abstract][Full Text] [Related]
18. Proteinases and plaque rupture: unblocking the road to translation. Newby AC Curr Opin Lipidol; 2014 Oct; 25(5):358-66. PubMed ID: 25089553 [TBL] [Abstract][Full Text] [Related]
19. VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts. Pérez-García S; Carrión M; Gutiérrez-Cañas I; González-Álvaro I; Gomariz RP; Juarranz Y J Cell Mol Med; 2016 Apr; 20(4):678-87. PubMed ID: 26818776 [TBL] [Abstract][Full Text] [Related]
20. Expression of ADAMs and their inhibitors in sputum from patients with asthma. Paulissen G; Rocks N; Quesada-Calvo F; Gosset P; Foidart JM; Noel A; Louis R; Cataldo DD Mol Med; 2006; 12(7-8):171-9. PubMed ID: 17088949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]